Neurocrine Biosciences (NBIX) is back in focus after presenting new CRENESSITY data at ENDO 2026, including first evidence in 11ß hydroxylase deficiency and two year cardiometabolic, bone, and quality of life findings.

For investors, the ENDO 2026 data arrives at a time when momentum in Neurocrine Biosciences shares has been strong, with a 90 day share price return of 30.92% and a 1 year total shareholder return of 34.36% building on solid multi year gains.

If this kind of clinical progress has your attention, it can also be useful to see what else is emerging in healthcare AI, starting with the 39 healthcare AI stocks.

With Neurocrine Biosciences now worth about US$16.9b and trading at US$168.52 a share, plus an indicated 61% intrinsic discount and a 15% gap to analyst targets, the key question is whether there is still a buying opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 12.6% Undervalued

Compared with the last close of $168.52, the most followed narrative for Neurocrine Biosciences points to a higher fair value anchored in its rare disease and CNS portfolio.

Rapid and consistent early adoption of CRENESSITY, with demonstrated high rates of reimbursement (>75%), robust clinical profile, and significant unmet need in CAH, indicates the likelihood of future blockbuster status, driving both top-line revenue growth and improved operating leverage.

Want to see why this narrative still arrives at a higher fair value despite a strong recent share run? The core assumptions pull together revenue growth, rising margins and a lower future earnings multiple than many investors might expect. The tension between those inputs and a discount rate just over 7% is where the real story sits.

Result: Fair Value of $192.88 (UNDERVALUED)

However, the Neurocrine Biosciences story also hinges on Crenessity uptake not stalling and on pricing or reimbursement pressure not eroding the earnings profile that analysts expect.

Next Steps

If this bullish tone around Neurocrine Biosciences has you interested, quickly review the underlying data to decide whether the optimism aligns with your view, then take a closer look at the 3 key rewards.

Looking for more investment ideas beyond Neurocrine Biosciences?

If Neurocrine Biosciences has sharpened your interest, use that momentum and keep evaluating fresh ideas so your watchlist always reflects your latest thinking.

• Target resilient income by scanning for companies with reliable payouts and higher yields through the 8 dividend fortresses.
• Spot potential value opportunities early by reviewing the screener containing 19 high quality undiscovered gems before other investors start paying attention.
• Prioritise capital preservation by focusing on companies that pass tighter risk filters using the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.